NOVARTIS AG Business Summary

Novartis AG operates as a pure-play innovative medicines company following the 2023 spinoff of its Sandoz generics division, primarily generating revenue through the development and commercialization of high-margin, patented prescription therapeutics. The company’s business is organized into four core therapeutic segments: Oncology, Immunology, Neuroscience, and Cardiovascular-Renal-Metabolic, supported by advanced technology platforms in radioligand therapy, gene and cell therapy, and xRNA. As of early 2026, Novartis is navigating a significant transition period characterized by the "patent cliff" of legacy blockbusters like Entresto, while driving growth through priority brands such as Kisqali, Kesimpta, and Pluvicto. Its primary direct competitors include AstraZeneca, Merck & Co., Roche, and Pfizer; within this peer group, Novartis maintains a leading market position by focusing on high-value specialty medicines and achieving industry-leading core operating margins of approximately 40%. Leadership is currently spearheaded by CEO Vasant (Vas) Narasimhan, an M.D. and former McKinsey consultant who has led the company since 2018, overseeing its strategic pivot toward high-growth biopharmaceuticals. The executive team includes CFO Harry Kirsch, who is serving his final month before his scheduled retirement on March 15, 2026, and CFO-elect Mukul Mehta, a 20-year veteran of the firm. The Board of Directors is chaired by Giovanni Caforio, M.D., the former CEO of Bristol Myers Squibb, who assumed the role in 2025 to bolster the company's clinical and commercial strategy. Historically, Novartis was established in 1996 through the then-record-breaking merger of Swiss life sciences giants Ciba-Geigy and Sandoz, a pedigree that continues to define its Basel-based corporate identity and extensive global R&D infrastructure.